Author

C. Cintas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Thibault· 2 shared C. Cayron· 2 shared F. Ramos-Delgado· 2 shared J. Guillermet-Guibert· 2 shared N. Therville· 2 shared A. Carrier· 1 shared A. Gomez-Brouchet· 1 shared A. V. Villard· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Thibault

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance

C. Cintas, T. Douche, Z. Dantes, E. Mouton-Barbosa, M.-P. Bousquet, C. Cayron, N. Therville, F. Pont, F. Ramos-Delgado, C. Guyon, B. Garmy-Susini, P. Cappello, O. Burlet-Schiltz, E. Hirsch, A. Gomez-Brouchet, , J. Guillermet-Guibert

This study identifies adaptive phosphoprotein responses to isoform-selective PI3K inhibitors in pancreatic cancer, showing that combination therapy can overcome resistance.

bioRxiv · Oct 8, 2020Cancer Biology

Pancreatic Cancer Intrinsic PI3Kα Activity accelerates Metastasis and rewires Macrophage Component

B. Thibault, F. Ramos-Delgado, E. Pons-Tostivint, N. Therville, C. Cintas, S. Arcucci, S. Cassant-Sourdy, G. Reyes-Castellanos, M. Tosolini, A. V. Villard, C. Cayron, R. Baer, J. Bertrand-Michel, D. Payen, H. Yan, , J. Guillermet-Guibert

This paper identifies PI3K pathway activation as a driver of metastatic progression in pancreatic cancer and shows that targeting PI3K can delay macro-metastatic evolution.

bioRxiv · Sep 23, 2020Cancer Biology